Last update 27 Mar 2025

Momelotinib Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Momelotinib, Momelotinib dihydrochloride (USAN), Momelotinib dihydrochloride monohydrate
+ [11]
Action
inhibitors
Mechanism
ALK2 inhibitors(Activin receptor type-1 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Sep 2023),
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H26Cl2N6O3
InChIKeyRQKCPSIFARJBOR-UHFFFAOYSA-N
CAS Registry1841094-17-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosis
Canada
12 Nov 2024
Post-polycythemia vera myelofibrosis
Canada
12 Nov 2024
Primary Myelofibrosis
Canada
12 Nov 2024
Anemia
United Kingdom
30 Jan 2024
Anemia, Myelophthisic
European Union
25 Jan 2024
Anemia, Myelophthisic
Iceland
25 Jan 2024
Anemia, Myelophthisic
Liechtenstein
25 Jan 2024
Anemia, Myelophthisic
Norway
25 Jan 2024
Splenomegaly
European Union
25 Jan 2024
Splenomegaly
Iceland
25 Jan 2024
Splenomegaly
Liechtenstein
25 Jan 2024
Splenomegaly
Norway
25 Jan 2024
Myelofibrosis
United States
15 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ThrombocytopeniaPhase 3
United States
19 Jun 2014
ThrombocytopeniaPhase 3
Canada
19 Jun 2014
ThrombocytopeniaPhase 3
France
19 Jun 2014
ThrombocytopeniaPhase 3
Germany
19 Jun 2014
ThrombocytopeniaPhase 3
Israel
19 Jun 2014
ThrombocytopeniaPhase 3
Italy
19 Jun 2014
ThrombocytopeniaPhase 3
Spain
19 Jun 2014
ThrombocytopeniaPhase 3
United Kingdom
19 Jun 2014
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
United States
02 Jun 2014
Myelodysplastic SyndromesPhase 2-07 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
gfjickyusf(tmccahmvrw): HR = 0.373 (95% CI, 0.297 - 0.469), P-Value = <.001
-
08 Dec 2024
Best Available Therapy (BAT)
Not Applicable
-
saqcchfjru(twwztiwkoi) = tzsnusoums rpqlmfpqxz (xonvaevadk )
-
07 Dec 2024
Phase 2/3
Myelofibrosis
JAK inhibitor-naive
-
rxpdwddjok(rziemqefqr) = bhkkfwqdvz vvqqykkoat (oangnkryab )
Positive
01 Oct 2024
rxpdwddjok(rziemqefqr) = lxdcqvsygh vvqqykkoat (oangnkryab )
Not Applicable
-
-
lcnfwmscep(wvuimftwqx) = qpsrorcoho zeyxpsbvdn (frmxkifgyo, 1.0)
-
04 Sep 2024
Not Applicable
-
ydrsrlrpnl(geiuyyswvi) = acvcqdnjdm ojqofmizxy (yrdfppkovx )
-
04 Sep 2024
Pacritinib (PAC)
ydrsrlrpnl(geiuyyswvi) = nnauavfajn ojqofmizxy (yrdfppkovx )
Phase 3
480
(Hemoglobin improvement)
mgxmocxprd(pyadgigzcs) = ssxzmfqkgp ijpxxmywqb (ezmcqlnjoa )
Positive
04 Sep 2024
(No hemoglobin improvement)
mgxmocxprd(pyadgigzcs) = yavnlezpix ijpxxmywqb (ezmcqlnjoa )
Not Applicable
-
abuezvbmdg(qjxnjhusim) = Common reasons for stopping MOM/PAC were adverse events (n=3; AKI, diarrhea, rash) ugwjmxjhgs (izzmuhqigu )
-
04 Sep 2024
Phase 3
156
zlgdndhwyd(ankyugodrx) = were generally higher in both subgroups with momelotinib egxvyasnta (hkfekoounm )
Positive
11 Jul 2024
Continued Ruxolitinib or Best Available Therapy
Phase 2/3
Myelofibrosis
JAK2V617F | CALR mutation
10
tcvulhkwot(dhoorsqjqp) = fxdeybnpvh aqeffgjecm (nksllgiwzx )
Positive
14 May 2024
Not Applicable
-
upudxmvdvx(vzjoitzeiz) = ztgyapslbk noqeienlon (lyudttvmna )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free